Skip to main content

Table 2 Adverse events in patients with advanced non-small cell lung cancer treated with erlotinib and pemetrexed

From: Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study

  Level 1 (n = 6) Level 2 (n = 6)
Hematologic G1 G2 G3 G4 G1 G2 G3 G4
 Neutropenia/Leukopenia 2 0 0 1 0 0 0 1
 Thrombocytopenia 2 1 0 0 1 1 0 0
 Anemia 3 3 0 0 4 1 0 0
Non-Hematologic G1 G2 G3 G4 G1 G2 G3 G4
 Nausea 3 0 0 0 2 1 0 0
 Vomit 1 0 0 0 0 0 0 0
 Anorexia 3 1 0 0 2 1 0 0
 Malaise 1 1 0 0 0 0 0 0
 Fatigue 2 1 0 0 3 0 0 0
 Diarrhea 1 0 0 0 1 0 1 0
 Constipation 1 0 0 0 2 0 0 0
 Hiccup 0 0 0 0 0 1 0 0
 Oral mucositis 1 0 0 0 3 0 0 0
 Rash 2 2 1 0 1 5 0 0
 Pruritus 1 0 1 0 2 0 1 0
 Paronychia 0 0 0 0 2 0 0 0
 Alopecia 0 0 0 0 1 0 0 0
 Peripheral Edema 0 0 0 0 0 1 0 0
 Alb 4 1 0 0 1 2 0 0
 AST 4 2 0 0 3 1 0 0
 ALT 0 3 1 0 2 2 0 0
 ALP 2 0 0 0 2 1 0 0
 Bilirubin 1 0 0 0 2 1 0 0
 Na 0 0 0 0 3 0 0 0
 K 2 0 0 0 1 0 0 0